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Abstract: The influence of effective room temperature on the radiochemical purity of
99mTc-radiopharmaceuticals was reported. This study was born from the observation that in
the isolators used for the preparation of the 99mTc-radiopharmaceuticals the temperatures can
be higher than those reported in the commercial illustrative leaflets of the kits. This is due,
in particular, to the small size of the work area, the presence of instruments for heating, the continuous
activation of air filtration, in addition to the fact that the environment of the isolator used for the
99mTc-radiopharmaceuticals preparation and storage is completely isolated and not conditioned.
A total of 244 99mTc-radiopharmaceutical preparations (seven different types) have been tested
and the radiochemical purity was checked at the end of preparation and until the expiry time.
Moreover, we found that the mean temperature into the isolator was significantly higher than 25 ◦C,
the temperature, in general, required for the preparation and storage of 99mTc-radiopharmaceuticals.
Results confirmed the radiochemical stability of radiopharmaceutical products. However, as required
in the field of quality assurance, the impact that different conditions than those required by the
manufacturer on the radiopharmaceuticals quality have to be verified before human administration.
Keywords: 99mTc-radiopharmaceuticals; radiochemical purity; radiopharmaceuticals quality control
1. Introduction
Radiopharmaceuticals labelled with technetium-99m (99mTc) have been, and still are, by far
the most used conventional agents for single photon emission computed tomography (SPECT).
These radiopharmaceuticals are prepared directly in hospital sites, using commercial lyophilized
kit formulations, by introducing the 99Mo/99mTc generator-eluted 99mTc-pertechnetate into the kit and
following the manufacturer’s instruction contained in the package leaflet. The instructions concern
not only the reconstitution procedure of the kit formulation, but also the storage conditions and the
associated quality control procedures. Environmental factors, such as temperature, humidity, and/or
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light, intrinsic factors, such as chemical-physical properties of the reagents and excipients present
in the kit formulations, pharmaceutical composition, quality of the generator eluted [99mTc]NaTcO4,
etc., could compromise the radiochemical purity of technetium-99m radiopharmaceuticals [1–4].
In particular, these factors could cause the formation of chemical impurities inducing phenomena such
as hydrolysis and oxidation-reduction reactions. Among the impurities, residual 99mTc-pertechnetate,
as consequence of non-reduction, and the reduced hydrolyzed technetium-99m [99mTc]TcO2,
due to the pertechnetate reduction, but not the complexation of the technetium-99m [5], lead to
consequent radiochemical purity (RCP) loss of the final radiopharmaceutical. The effect of many
listed factors on RCP of some 99mTc-radiopharmaceuticals have been investigated in the past,
e.g., the technetium-99 presence excess in solution [2]; the humidity influence on radiochemical
purity of [99mTc]Tc-ECD and [99mTc]Tc-MIBI [1]; the saline storage condition, used for the preparation
of [99mTc]Tc-HMPAO [6]; and the effect of increased temperature on the labelling efficiency
of some 99mTc-radiopharmaceutilcals [7]. In particular, Maksin et al. exposed some compounds,
such as pyrophosphate (PyP), dicarboxypropane diphosphonate (DPD), dimercaptosuccinate (DMS),
and Sn-colloid, at 37 ◦C for different time intervals before labelling with 99mTc-pertechnetate.
They found that, only for 99mTc-Sn-colloids, the increased temperature exposure had no effect
on the expected labelling yield in the routine quality control. Taking into account these
results and in particular, considering that in our nuclear medicine hospital unit the preparation
of 99mTc-radiopharmaceuticals takes place inside a not conditioned isolator and, therefore,
the temperature could be significantly higher than required by manufacturer, we decided to investigate
the effect of the temperature on the radiochemical purity of radiopharmaceuticals at the end of
the preparation and during the storage before injection. In fact, while the temperature required by
manufacturers for the production of 99mTc-radiopharmaceuticals is variable, the radiolabelled kits
storage temperature value has to be <25 ◦C. Furthermore, the cited works [6,7] analyzed different
aspects from this that we have investigated.
The aim of this work was to investigate the effect of storage temperature on the radiochemical
purity of Ceretec (GE Healthcare, Milan, Italy), MAASOL (GE Healthcare, Milan, Italy), Nanocoll
(GE Healthcare, Milan, Italy), Renocis (IBA molecular Italy S.r.l., Milan, Italy), Technemibi
(Mallinckrodt, Petten, The Netherlands), Technescan HDP (Mallinckrodt, Petten, The Netherlands)
and Technescan MAG3 (Mallinckrodt, Petten, The Netherlands).
2. Materials and Methods
All materials used and the methods followed are described in the manufacturer’s instructions.
These instructions represent the reference for operators in the production and quality control of
radiopharmaceuticals. All tools and equipment described in the following sections were initially
qualified (installation qualification, operational qualification, and performance qualification) and
periodically re-qualified.
2.1. 99mTc-Radiopharmaceuticals Preparation
99Mo/99mTc Drytec generators (25 GBq of 99Mo) were purchased by GE (GE Healthcare S.r.l,
Milan, Italy). Generator elution and 99mTc-radiopharmaceuticals synthesis from kit formulation were
conducted into a class A laminar flow isolator (Murphil-Tc, MecMurphil S.r.l, Ferrara, Italy, Figure 1),
placed in a class D room.
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Figure 1. Murphil-Tc (MecMurphil): the isolator (a) and the work area inside the isolator (b). 
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refrigerator (Medical Proget, KW control, marketed by MecMurphil S.r.l, Ferrara, Italy).  
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(GE Healthcare) 
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(GE Healthcare) 
[99mTc]Tc-nanocolloid 2–8 °C (1 year) <25 °C (6 h) 
Renocis  
(IBA molecular) 
[99mTc]Tc-DMSA 2–8 °C (1 year) 15–25 °C (8h) 
Technemibi  
(Mallinckrodt) 
[99mTc]Tc-MIBI <25 °C (2 year) <25 °C (10 h) 
Technescan HDP  
(Mallinckrodt) 
[99mTc]Tc-HDP <25 °C (2 year) <25 °C (8 h) 
Technescan MAG3  
(Mallinckrodt) 
[99mTc]Tc-MAG3 2–8 °C (1 year) <25 °C (8 h) 
1 The temperature and time values of storage have been obtained from the most recently approved 
package inserts. 
Kit reconstitution was performed according to the methods described in the package insert 
included within the commercial kits. In order to evaluate radiochemical purity in the worst case, the 
volumes and the activities used during the reconstitution of the kit were the maximum possible. 
When required by the synthesis process, e.g., in the [99mTc]Tc-MAG3 and [99mTc]Tc-MIBI production 
(Table 2), a digital dry heater (AccuBlockTM, LabNet, purchased by MecMurphil S.r.l, Ferrara, Italy) 
was used. After labelling with 99mTc-pertechnetate, the radiopharmaceuticals solutions were stored 
inside the isolator until the complete fractionation. Continuous temperature monitoring inside the 
isolator was performed using calibrated graphic recorder KT621 (Dickson, provided by the 
University Hospital of Ferrara). The temperature was recorded on a 101 mm diameter paper disc 
using a red pen (Figure 2).  
Figure 1. Murphil-Tc (MecMurphil): the isolator (a) and the work area inside the isolator (b).
Freeze-dried kits (Table 1) have been stored until their use in a temperature-controlled refrigerator
(Medical Proget, KW control, marketed by MecMurphil S.r.l, Ferrara, Italy).
Table 1. Freeze-dried kits analyzed and the temperature required by the manufacturer for the storage
of lyophilized kits and radiopharmaceutical preparations.
Name Radiopharmaceuticals Kit Storage Conditions 1
Radiopharmaceuticals
Storage Conditions 1
Ceretec
(GE Healthcare) [
99mTc]Tc-HMPAO <25 ◦C (1 year) <25 ◦C (30 min)
MAASOL
(GE Healthcare) [
99mTc]Tc-albumin colloid 2–8 ◦C (2 year) <25 ◦C (6 h)
Nanocoll
(GE Healthcare) [
99mTc]Tc-nanocolloid 2–8 ◦C (1 year) <25 ◦C (6 h)
Renocis
(IBA molecular) [
99mTc]Tc-DMSA 2–8 ◦C (1 year) 15–25 ◦C (8h)
Technemibi
(Mallinckrodt) [
99mTc]Tc-MIBI <25 ◦C (2 year) <25 ◦C (10 h)
Technescan HDP
(Mallinckrodt) [
99mTc]Tc-HDP <25 ◦C (2 year) <25 ◦C (8 h)
Technescan MAG3
(Mallinckrodt) [
99mTc]Tc-MAG3 2–8 ◦C (1 year) <25 ◦C (8 h)
1 The tempe re and time values of storage hav been o tai ed from the m st rec ntly approved package inserts.
Kit reconstitution was performed according to the methods described in the package insert
included within the commercial kits. In order to evaluate radiochemical purity in the worst case,
the volumes and the activities used during the reconstitution of the kit were the maximum possible.
When required by the synthesis process, e.g., in the [99mTc]Tc-MAG3 and [99mTc]Tc-MIBI production
(Table 2), a digital dry heater (AccuBlockTM, LabNet, purchased by MecMurphil S.r.l, Ferrara, Italy)
was used. After labelling with 99mTc-pertechnetate, the radiopharmaceuticals solutions were stored
inside the isolator until the complete fractionation. Continuous temperature monitoring inside the
isolator was performed using calibrated graphic recorder KT621 (Dickson, provided by the University
Hospital of Ferrara). The temperature was recorded on a 101 mm diameter paper disc using a red pen
(Figure 2).
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Figure 2. Graphic recorder (a,b) diagram disks ( ickson); and (c) recorder position in the work area.
A preliminary temperature registration, in order t ascertain the temperature fl ctuation,
was made for 24 h/7 days for three weeks inside the isolator (hot cell closed): on the outer edge
of the paper disc are indicated the different days of the week divided into three hours-groups;
the temperatures, printed on the disk in the range from −30 ◦C to +50 ◦C, are then detected by
a graduated scale with a precision of ±2.5 ◦C. Every Friday, the paper disk was replace and he data
were collected and registered into datasheets. The same temperature control has been continuously
performed during all the radiochemical purity three months monitoring.
2.2. 99mTc-Radiopharmaceuticals Radiochemical Purity Assessment
The radiochemical purity (RCP) of radiopharmaceuticals was evaluated immediately after the
preparation (time = 0), in the middl and at the end of th expiry time indicated by the manufacturer
(Table 1). The radiochemical purity was measured using methods specified by manufacturer,
with the exception of Technescan (Mallinckrodt) for which he following chrom tographic system
was used [8]: mobile phase, 54/45/1 (physiological/methanol/glacial acetic acid, v/v/v) and
stationary phase, RP-18 plates (Merck, Serono, Roma, Italy). The radioactivity distribution’s
determination was performed by a scanning radio-chromatography detection system for thin
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layer chromatography (Cyclone instrument equipped with a phosphor imaging screen and an
OptiQuant image analysis software; PerkinElmer, Waltham, MA, USA). The solvents were obtained
from Sigma Aldrich (Sigma-Aldrich, Milan, Italy); only methanol was obtained from VWR
(VWR International, Fontanay sous Bois, France); MilliQ (18.2 MΩ) water was obtained from a
Direct Q® system (Millipore, Darmstadt, Germany); physiological solution Fresenius KABI was
obtained from Medexitalia (Medexitalia, Roma, Italy). All mobile phases used for quality control
of radiopharmaceuticals were stored in a controlled and ventilated refrigerator (Antiscintilla 400
ECT-F-TOUCH, Fiocchetti, marketed by MecMurphil S.r.l, Ferrara, Italy); the stationary phases were
stored in a special dehumidified container. ITLC-SG and ITLC-SA plates were obtained from Agilent
Technology (Folsom, CA, USA); Whatman n.1 (Merck, Serono, Roma, Italy). Table 2 summarizes all of
the experimental variables.
Table 2. Summary of the experimental conditions. We chose to use, for each preparation, the maximum
activity and the maximum volume allowed by the manufacturer.
Compound Synthesis Quality Control System Quality Control Time
Ceretec
(GE Healthcare)
[99mTc]Tc-HMPAO
N = 24
Volume: 5 mL
Activity: 1.10 GBq 1
Incubation Time: 30 s
Package leaflet: 03/2016
TLC-SA
Methylethylketone (MEK) 0 min, 15 min, 30 min
TLC-SA
physiological solution
MAASOL
(GE Healthcare)
[99mTc]
Tc-albumin colloid
N = 24
Volume: 8 mL
Activity: 2.96 GBq
Incubation Time: 5 min
Package leaflet: 03/2015
ITLC-SG
Methanol:water
(85:15, v:v)
0 h, 3 h, 6 h
Nanocoll
(GE Healthcare)
[99mTc]Tc-nanocolloid
N = 80
Volume: 5 mL
Activity: 5.55 GBq
Incubation Time: 30 min
Package leaflet: 11/2015
TLC-SA Methanol:water
(85:15, v:v) 0 h, 3 h, 6 h
Renocis
(IBA molecular)
[99mTc]Tc-DMSA
N = 8
Volume: 6 mL
Activity: 3.70 GBq
Incubation Time: 10 min
Package leaflet: 05/2011
Whatman n.1
MEK 0 h, 4 h, 8 h
Technemibi
(Mallinckrodt)
[99mTc]Tc-MIBI
N = 24
Volume: 3 mL
Activity: 11.10 GBq
Incubation Time: 10 min, 100 ◦C
Package leaflet: 10/2014
Baker flex aluminum oxide
Ethanol >95% 0 h, 5 h, 10 h
Technescan
HDP (Mallinckrodt)
[99mTc]Tc-HDP
N = 60
Volume: 10 mL
Activity: 11.10 GBq
Incubation Time: 30 s
Package leaflet: 08/2017
TLC-SG
13.6% sodium acetate 0 h, 4 h, 8 h
TLC-SG
MEK
Technescan MAG3
(Mallinckrodt)
[99mTc]Tc-MAG3
N = 24
Volume: 10 mL
Activity: 2.96 GBq 2
Time: 10 min, 120 ◦C
Package leaflet: 02/2017
RP-18
54/45/1
(saline/methanol/glacial
acetic acid)
0 h, 4 h, 8 h
1 Fresh sodium pertechnetate (not older than 2 h) obtained by generator eluted not more than 24 h before.
2 Fresh sodium pertechnetate obtained by generator (generator not older than 1 week from manufacturing) eluted
not more than 24 h before. Where not specified, the incubation temperature during the synthesis, inside the isolator,
was detected by our measurement. Finally, the production process of 99mTc-radiopharmaceuticals is constantly
subjected to the Fill average test.
3. Results and Discussion
The illustrative leaflets of the commercial kits used for the preparation of
99mTc-radiopharmaceuticals, set out in detail all the preparations conditions, the quality controls to be
executed, the values of the radiochemical purity and storage conditions, such as the temperature to
which the radiopharmaceutical must be preserved before injection.
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The small size of the work area, the presence of instruments for heating, the continuous activation
of air filtration, the internal lighting, in addition to the fact that the environment of the isolator, used for
the preparation and holding of 99mTc-radiopharmaceuticals, is completely isolated and not conditioned
(Figure 1), could affect the temperature in the work area. At the moment, to our knowledge, there are
no conditioning-equipped isolators, for nuclear medicine, available on the market even though the
nuclear medicine community has chorally underlined this problem to the hot cells producers.
These potential discrepancies of temperatures and its influence on the radiochemical purity of
radiopharmaceuticals have been deeply investigated in this work. The first objective was to verify the
real temperature inside the isolator, with a calibrated instrument (Figure 1). The temperature required
by manufacturers for the production of radiopharmaceuticals is variable, but the storage value must be
<25 ◦C. Data were collected for three months (7 days/24 h) and the results are summarized in Table 3.
The data collected through the graphical temperature recorder were firstly transcribed and subdivided
by time slots in an Excel sheet. From these data, it was possible to determine the temperature average
values and error, on different days of the week, divided by time slots.
Table 3. Average and standard error of temperature detected on the work surface inside the isolator.
Day 1 Temperature ◦C (8:00–12:00) Temperature ◦C (12:00–18:00)
Monday 29.0 ± 1.4 30.0 ± 1.4
Tuesday 30.0 ± 1.4 30.0 ± 1.4
Wednesday 30.0 ± 1.4 29.0 ± 1.4
Thursday 30.0 ± 1.4 31.0 ± 1.4
Friday 29.0 ± 1.4 30.0 ± 1.4
Saturday/Sunday 23.0 ± 1.4 23.0 ± 1.4
1 The peak of activity (production and quality control of radiopharmaceuticals) is from Monday to Friday from
8:00 to 12:00 a.m.; Saturday and Sunday the Nuclear Medicine Unit is closed, therefore we consider 23 ◦C as the
standard temperature during the non-activity period (isolator-off). The weekly radiopharmaceuticals production
program is standardized and is repeated with minimal variations.
The results show a significant difference in temperatures compared to the reference standard
(<25 ◦C). In the afternoon the instrument used to heat is off, but, despite this, the temperature,
on average, results higher than 25 ◦C; this fact can be explained, most likely, by the operation of the
isolator ventilation systems, which causes air heating. Establishing that the internal temperature
of the isolator differed from that required for storage, we evaluated how much this temperature
difference could affect the RCP of radiopharmaceuticals during the storage period, which also
includes the fractionation of the preparation to be administered to the patients. A total of
244 99mTc-radiopharmaceutical preparations (seven different types), performed in our nuclear medicine
unit, have been tested in this work. Table 4 shows the RCP values of the preparations, reported as
the mean and standard deviation of the individual values found during the three months of the test
run. Along with these values, the temperature mean values detected during the RCP determination
were added.
The results show that the temperatures are well above the reference standards but the RCP
values are always higher than those established by manufacturers. The overall analysis of the results
showed no anomalies with respect to the radiopharmaceutical quality of the products intended for
administration to the patients at the time of preparation or at the limit of their stability. Moreover,
all “media fill” tests confirmed the sterility of the radiopharmaceutical products.
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Table 4. RCP values expressed as % media ± SD and temperature values expressed as
average ± standard error.
Radiopharmaceuticals RCP-1 (%) 1 RCP-2 (%) 2 RCP-3 (%) 3
RCP (%)
Expected Value
Ceretec
(GE Healthcare)
[99mTc]Tc-HMPAO
N = 24
98.1 (±1.0)
31.0 ◦C (±0.5)
94.8 (±1.1)
31.0 ◦C (±0.5)
94.5 (±2.1)
31.0 ◦C (±0.5) ≥80%
MAASOL
(GE Healthcare)
[99mTc]Tc-albumin
colloid
N = 24
100.0 (±0.0)
32.0 ◦C (±0.5)
100.0 (±0.0)
32.0 ◦C (±0.5)
100.0 (±0.0)
30.0 ◦C (±0.5) ≥95%
Nanocoll
(GE Healthcare)
[99mTc]Tc-nanocolloid
N = 80
99.10 (±0.09)
29.0 ◦C (±0.3)
100.0 (±0.0)
29.0 ◦C (±0.3)
99.3 (±1.2)
29.0 ◦C (±0.3) ≥95%
Renocis
(IBA molecular)
[99mTc]Tc-DMSA
N = 8
100.0 (±0.9)
33.0 ◦C (±0.9)
100.0 (±0.9)
29.0 ◦C (±0.9)
100.0 (±0.9)
29.0 ◦C (±0.9) ≥95%
Technemibi
(Mallinckrodt)
[99mTc]Tc-MIBI
N = 24
98.4 (±0.2)
29.0 ◦C (±0.5)
99.1 (±0.7)
29.0 ◦C (±0.5)
98.9 (±0.8)
29.0 ◦C (±0.5) ≥94%
Technescan HDP
(Mallinckrodt)
[99mTc]Tc-HDP
N = 60
100.0 (±1.2)
33.0 ◦C (±0.3)
98.8 (±1.6)
33.0 ◦C (±0.3)
98.9 (±1.8)
31.0 ◦C (±0.3) ≥95%
Technescan MAG3
(Mallinckrodt)
[99mTc]Tc-MAG3
N = 24
100.0 (±0.0)
30.0 ◦C (±0.5)
99.5 (±0.5)
30.0 ◦C (±0.5)
99.4 (±0.5)
29.0 ◦C (±0.5) ≥94%
1 RCP-1 = value at the end of the labelling and temperature at the time of test; 2 RCP-2 = value determined
in the middle between the labelling and the expiry time and temperature at the time of test; 3 RCP-3 = value
determined at the expiry time and temperature at the time of test; expected value is the standard value required by
the manufacturer for administration to patients.
4. Conclusions
The radiochemical purity of radiopharmaceuticals plays a key role in the protection of the patient
to which the minimum undesirable exposure must be ensured. The evaluation of the impact that
different conditions may have on the radiopharmaceuticals quality, it is crucial. The results of this work
confirmed that the temperature variability, measured inside the isolator, does not have any effect on
the radiochemical purity of radiopharmaceutical products until the expiry time. However, as required
in the field of quality assurance, an assessment of the impact that conditions, other than those required
by the manufacturer have on the radiopharmaceuticals for human use, is needed.
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